| Date Filed | Type | Description |
| 08/25/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/22/2023 |
4
| WYZGA MICHAEL S (Director) has filed a Form 4 on X4 Pharmaceuticals, Inc|
Txns:
| Bought 25,000 shares
@ $1.195, valued at
$29.9k
|
|
| 08/16/2023 |
3
| Arbet-Engels Christophe (Chief Medical Officer) has filed a Form 3 on X4 Pharmaceuticals, Inc |
| 08/11/2023 |
4
| Stewart Murray (Interim Chief Medical Officer) has filed a Form 4 on X4 Pharmaceuticals, Inc|
Txns:
| Granted 269,893 shares
@ $0
Sold 130,056 shares
@ $1.06, valued at
$137.9k
|
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/05/2023 |
4
| DiBiase Mary (COO) has filed a Form 4 on X4 Pharmaceuticals, Inc|
Txns:
| Sold 464 shares
@ $1.89, valued at
$877 |
|
| 07/05/2023 |
4
| Mostafa Adam S. (CFO) has filed a Form 4 on X4 Pharmaceuticals, Inc|
Txns:
| Sold 2,641 shares
@ $1.89, valued at
$5k
|
|
| 06/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
4
| DiBiase Mary (COO) has filed a Form 4 on X4 Pharmaceuticals, Inc|
Txns:
| Sold 857 shares
@ $2.23, valued at
$1.9k
|
|
| 06/16/2023 |
4
| Mostafa Adam S. (CFO) has filed a Form 4 on X4 Pharmaceuticals, Inc|
Txns:
| Sold 5,417 shares
@ $2.22, valued at
$12k
|
|
| 06/16/2023 |
4
| Ragan Paula (President and CEO) has filed a Form 4 on X4 Pharmaceuticals, Inc|
Txns:
| Sold 6,724 shares
@ $2.23, valued at
$15k
|
|
| 06/16/2023 |
SC 13G
| MILLENNIUM MANAGEMENT LLC reports a 5.2% stake in X4 PHARMACEUTICALS, INC. |
| 06/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/01/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 06/01/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 05/31/2023 |
4
| Ragan Paula (President and CEO) has filed a Form 4 on X4 Pharmaceuticals, Inc|
Txns:
| Sold 6,292 shares
@ $1.95, valued at
$12.3k
|
|
| 05/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/26/2023 |
SC 13D/A
| Growth Equity Opportunities 18 VGE, LLC reports a 10% stake in X4 Pharmaceuticals, Inc. |
| 05/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events ... |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/21/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/21/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
4
| DiBiase Mary (COO) has filed a Form 4 on X4 Pharmaceuticals, Inc|
Txns:
| Sold 18,192 shares
@ $0.84, valued at
$15.3k
|
|
| 03/13/2023 |
4
| Mostafa Adam S. (CFO) has filed a Form 4 on X4 Pharmaceuticals, Inc|
Txns:
| Sold 52,500 shares
@ $0.84, valued at
$44.1k
|
|
|